Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nontuberculous Mycobacterial Disease Clear all
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

NCT01585766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Forms
Interventions
MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting Phase 2 Interventional

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794
View directory record Official record
Conditions
Post-COVID / Long-COVID
Interventions
Placebo, Sipavibart
Drug · Biological
Lead sponsor
Nancy Klimas
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2Phase 3 Interventional

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

NCT03672630
View directory record Official record
Conditions
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Interventions
Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002267
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
31
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677543
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting No phase listed Observational

Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)

NCT06155747
View directory record Official record
Conditions
Nontuberculous Mycobacterial Pulmonary Infection, Outbreak Investigation, Healthcare Associated Infection, Mycobacterium Infections
Interventions
Epidemiologic investigation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Month to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

NCT03748992
View directory record Official record
Conditions
Nontuberculous Mycobacterium Infection
Interventions
gNO
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Portland, Oregon • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

NCT00002122
View directory record Official record
Conditions
Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin, Rifabutin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:04 AM EDT
Active, not recruiting Phase 2 Interventional

Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

NCT02968212
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Clofazimine, sugar pill
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 1 Interventional

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

NCT00111397
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Cytokine therapy, Interferon Gamma, GM-CSF
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS

NCT00001047
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Clofazimine, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria

NCT01315236
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Liposomal amikacin for inhalation (LAI), placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002032
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Irvine, California • Sylmar, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:04 AM EDT
Recruiting Phase 2 Interventional

Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)

NCT07094711
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous
Interventions
Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

NCT00000947
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex

NCT03164291
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infections
Interventions
Rifabutin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1984 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 23, 2026, 10:04 AM EDT
Completed No phase listed Observational

The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients

NCT00000860
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional

A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS

NCT00002343
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Weight and/or Obesity on Dapsone Drug Concentrations

NCT01165840
View directory record Official record
Conditions
Obesity, Leprosy, Tuberculosis
Interventions
Dapsone
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 4 Interventional

Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease

NCT00598962
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Azithromycin, Rifabutin/rifampin
Drug
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2017
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 23, 2026, 10:04 AM EDT
Completed No phase listed Observational

Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease

NCT00368446
View directory record Official record
Conditions
Cystic Fibrosis, Pseudohypoaldosteronism, Nontuberculous Mycobacterial Infection, Chronic Granulomatous Disease, Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of Standard Drugs for Mycobacterium Avium Complex

NCT04287049
View directory record Official record
Conditions
Mycobacterium Avium Complex
Interventions
Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 10:04 AM EDT
Completed No phase listed Observational

Mycobacterium Avium Intracellulare Complex (MAC) Study

NCT00826423
View directory record Official record
Conditions
Mycobacterium Avium Intracellulare Complex (MAC)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Jul 23, 2026, 10:04 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

NCT00000857
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 10:04 AM EDT